Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary hyperoxaluria type 1: is genotyping clinically helpful?

Ernst Leumann, Bernd Hoppe

    Pediatric Nephrology (Berlin, Germany)
    |March 18, 2005
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Interleukin-17A mediates cardiorenal injury in oxalate nephropathy.

    Cardiovascular research·2026
    Same author

    Development of an Exergaming-Intervention for Children and Adolescents During Hemodialysis: A Pilot Study.

    Studies in health technology and informatics·2026
    Same author

    Exergaming as a promising approach to promote physical activity in children and adolescents during hemodialysis?

    Pediatric nephrology (Berlin, Germany)·2026
    Same author

    RNA interference medication and transplantation procedures in patients with primary hyperoxaluria type 1.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2025
    Same author

    PHYOX3: Nedosiran Long-Term Safety and Efficacy in Patients With Primary Hyperoxaluria Type 1.

    Kidney international reports·2025
    Same author

    Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease.

    The Journal of clinical investigation·2025

    Mutation analysis for primary hyperoxaluria type 1 (PH1) has limitations in diagnosis and prognosis. While genetically informed, it requires complementary tests for definitive patient management.

    Area of Science:

    • Genetics
    • Biochemistry
    • Medical Management

    Background:

    • Primary hyperoxaluria type 1 (PH1) management is debated regarding the utility of mutation analysis.
    • The AGXT gene encodes alanine:glyoxylate aminotransferase (AGT), with ~50 known mutations, but common variants explain <50% of cases in Western populations.
    • No simple screening test exists for PH1 mutations.

    Discussion:

    • Mutation analysis can aid PH1 diagnosis, especially for liver transplantation, but liver biopsy is often needed to assess AGT activity.
    • Prognosis prediction is challenging due to significant clinical variability even with identical AGXT mutations.
    • While some genotypes (e.g., 508G>A) suggest better prognosis and others (e.g., 33insC) worse, exceptions are frequent, limiting precise prediction.

    Key Insights:

    Related Experiment Videos

    • Genetic testing for PH1 is clinically useful but has limitations.
    • Pyridoxine responsiveness may be anticipated in certain genotypes (508G>A, 454T>A), but empirical testing is still recommended for all patients.
    • Definitive diagnosis and prognosis require integrating genetic data with clinical and biochemical assessments.

    Outlook:

    • Further research may refine the prognostic value of specific PH1 mutations.
    • Development of more comprehensive genetic screening tools could improve PH1 diagnosis.
    • Personalized treatment strategies for PH1 may benefit from a deeper understanding of genotype-phenotype correlations.